Lakefront Biotherapeutics (LKFT) Finished Goods (2020 - 2023)

Lakefront Biotherapeutics (LKFT) has reported Finished Goods for 4 consecutive years, with $6.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Finished Goods fell 19.99% year-over-year to $6.6 million; the TTM figure through Dec 2023 stood at $6.6 million (down 19.99% YoY), while the FY2023 annual figure was $6.6 million, down 19.99% from the prior year.
• Finished Goods retreated to $6.6 million in Q4 2023 per LKFT's latest filing, from $8.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $8.2 million in Q4 2022 and bottomed at $42922.4 in Q4 2020.
• Historically, Finished Goods has averaged $5.1 million across 4 years, with a median of $6.1 million in 2023.
• Annual changes were most pronounced in 2021 — Finished Goods jumped 12804.92% — and 2023, when it declined 19.99%.
• Lakefront Biotherapeutics' Finished Goods stood at $42922.4 in 2020, then jumped by 12804.92% to $5.5 million in 2021, then jumped by 48.51% to $8.2 million in 2022, then fell by 19.99% to $6.6 million in 2023.
• Business Quant data shows LKFT's Finished Goods at $6.6 million in Q4 2023, $8.2 million in Q4 2022, and $5.5 million in Q4 2021.